Jul2

Does Size Always Matter?

How Pharma Engages With Its Followers Online

Social Network Blog Image_EDPharma is investing more heavily in social media than ever before; tweets are up 530% since 2013 and Twitter followers have increased by nearly 300%. So far, so good. Because more followers means more opportunities to get involved, and the more impact you make online, right?

But engaging in genuine, meaningful conversations about a corporate brand isn’t easy, and it’s important to ensure we don’t fall into the trap of focusing too much on numbers and not enough on engagement. Companies need to ensure they don’t build followers just to push out messages to anyone willing to pay attention. While people are increasingly more open to finding new knowledge on social media, they don’t want to wade through hundreds of pages of information, images or tweets to do so.

The balance between community size versus engagement is becoming more and more of a priority, and formed one of the focus areas for a recent report published by Ogilvy Healthworld, part of Ogilvy CommonHealth Worldwide (the health behavior specialists of Ogilvy & Mather).The report, Connecting the Dots: Which Pharma Companies Are Succeeding in the Social Media Space?, was the first of its kind to provide insights into which pharma companies are leading the way in integrated social media marketing strategies.

“We know that some pharma companies have been cautious in their approach to social media, but our report clearly demonstrates a dramatic and successful increase in activity,” said Rebecca Canvin, Social Media Manager at Ogilvy Healthworld, adding: “Social media has changed the way pharma companies communicate—it allows them to build corporate reputation and engage in genuine, meaningful conversations with audiences. For companies who want to stand out from the crowd, it’s time to be brave, get personal, educate and integrate social media into their wider marketing strategy.”

Interestingly, companies that ranked most highly in the audit weren’t necessarily those with the largest communities, but those who engaged their audiences through frequent activity. And it’s not hard to understand why the more active companies enjoy the most engagement with their followers—after all, social media in its very nature demands participation and interaction. But the companies that do it well manage to create content that is less about the organization and more about connection points or interests that followers share.

The report highlights that although the focus for pharma companies is still on building brand profile, the priority is turning to attracting, keeping and engaging with loyal followers. And to do this, the onus needs to shift to “quality over quantity.” It’s more powerful to engage with a small group of passionate followers, whether they’re consumers, doctors or media, than to blast one message to 10,000 followers and “see what sticks.”

And loyal followers will reward companies who engage continuously in this way—so really, shouldn’t we all be asking, how much does size matter?

Connecting the dots - infographic UK Post

To find out more on Connecting the Dots: Which Pharma Companies Are Succeeding in the Social Media Space? please visit: http://bit.ly/1P5R5Ws

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Apps, behavior change, Brand Awareness, Branding, Content Strategy, Culture, Data, Design, Digital, Health & Wellness, Healthcare Communications, Public Relations, Social Media, Strategy, Technology | Comments closed
Jun22

Google Changes Search Ad Format For Pharma Brands

Search-For-PharmaGoogle has announced that it will be updating the Google Search ad format it offers to healthcare and pharmaceutical brands. This change affects support for pharmaceutical brands with black box warnings and those that require adverse event information as part of the ad.

URL architecture for black box brands

As of July 20, 2015, Google will be moving to a common AdWords format that no longer supports an additional line of copy and additional URL for black box brands and those requiring adverse event language. This is an evolution that is optimized for its paid search marketing solution that has been available to pharmaceutical advertisers for the last five years.

An example of how a brand might be using search engine marketing in Google AdWords before and after the July 20th update:

Pre-July 20th AdWords Example:
Brand Ad 1
Post-July 20th AdWords Example:
Brand Ad 2

 

 

 

What does this change mean for pharma brands?
Brands that are currently using Google AdWords for marketing will need to consider a rewrite of existing creative and landing pages. The pages that the new AdWords ad links to will need to prominently feature adverse events information for the product. This will require revisiting of search marketing strategies as well as potential user experience and design changes to optimize inbound traffic from paid search campaigns.

Brands currently using paid search programs with Google should leverage Google’s Sitelinks feature, which provides several links to content within a product website within the AdWords format. Product managers and agencies should also reinvest in paid mobile search with this change, as there is a broader efficiency with this change in having a single ad format for all platforms (desktop and mobile search).

Post-July 20th AdWords Example with Sitelinks:
Brand Ad 3

The changes to Google’s AdWords program will have a significant impact on pharma brand website marketing performance as well as the cost of paid search solutions currently used for search engine marketing programs. Expect to see changes in your category as well as behavioral changes for your paid and organic search performance.

Next steps
The changes to Google’s AdWords program will affect every brand using paid search for healthcare professional and consumer engagement. Work with your agency partner to identify the best counter-measures for these changes and how to recalculate your performance metrics.

Ogilvy CommonHealth offers digital strategy, content strategy, creative development, and analytics services for all of our clients to guide brand leadership through these and any future changes to search engine marketing and market changes in digital and traditional media.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Analytics, Apps, content marketing, Content Strategy, copywriting, Creativity, Data, Design, Digital, Healthcare Communications, Media, Media Placement, Pharmaceutical, SEO, Social Media, Strategy, Technology | Comments closed
May28

Satisfying Patient Needs Across Generations via Patient Portals

When it comes to healthcare, patients from the “Greatest Generation” to Millennials want three things: 1) a strong patient-physician relationship, 2) easy-to-understand healthcare information, and 3) this information? preferably in a digital format. How do we accomplish all three? Before we answer that question, let’s take a look at how different generations access healthcare information.

Monica Wong Blog Image

The “Greatest Generation” (Age 65+)
While almost 60% of people ages 65 and older use the Internet on a daily basis, this generation of patients are heavily influenced by their doctors when it comes to recommendations, health information and referrals. However, children and caretakers of this generation, Baby Boomers, may also play a role in making these decisions on behalf of the “Great Generation.”

Baby Boomers (Age 45-65)
While this generation is also influenced by physicians, Boomers are more likely than the “Greatest Generation” to research their options, challenge assumptions and rely on peer-to-peer conversations to make their healthcare decisions. 79% of Baby Boomers go online every day or almost every day. A Google/Nielsen Boomer Survey also reported that 78% of Baby Boomers have searched for health information after seeing something on TV. Baby Boomers also influence healthcare decisions of their Gen X and Millennial children.

Gen X (Age 30-45)
According to research done by Smith & Jones Healthcare Marketing, Gen X are only moderately responsive to healthcare advertising. Since this generation is the first to experience the digital age, Gen X shops for healthcare like they do for retail goods and services. They are partial to TV and in-office messages compared to other forms of marketing channels, but they also have a tendency to search for ratings and reviews online, as experience matters to them.

Millennials (Age 20-30)
Like Gen X, Millennials highly value positive patient experiences. They are young and healthy and as a result, they mainly use healthcare for primary care, urgent care and OB/GYN. Online advertising, TV and in-office messages are the best ways to reach them close to the care decision. Millennials seek information from a variety of sources, including online, social networks and word of mouth.

Satisfying Patient Needs Across Generations With Patient Portals
What do these generations of patients all have in common? They want positive patient experiences with their physicians. They want information they can easily understand and they want easy access to it online. So how do we satisfy these needs? Patient portals. Why? Because increasing positive patient outcomes and experiences begins with making physicians more accessible when patients have concerns. Physicians can distribute timely and relevant information to their patients on a digital platform that can be accessed 24/7. According to the American Academy of Family Physicians, 41% use portals for secure messaging, 35% use them for patient education, and 30% use them for prescribing medications and scheduling appointments.

How Can Marketers Leverage Patient Portals?
By repurposing existing healthcare marketing material and creating a depository for digital assets, these resources can be made available to HCPs who can then share these assets with their patients. Their patients will likely be more receptive to information as it is coming from a trusted source, their physicians, and through a channel they have easy access to. However, there are limitations.

Opportunities to Take Patient Portals to the Next Level
For elderly patients, additional features like the ability to increase portal font size is a simple fix. For digital natives, mobile-optimized portals can facilitate prescription refills and requests as well as schedule appointments. For non-native English speakers, portals available in different languages can dramatically improve patient services. But for those who do not have access to the Internet, we’ll have to find a way to close that gap. If you have any thoughts, please share in the comments below.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in Analytics, Data, Design, Digital, Health & Wellness, Healthcare Communications, Technology, Wearable Health Technology | Comments closed
May4

The Digital Health Revolution: Transforming the Patient Journey

The Digital Health Revolution Blog Image 2Around the world, one in every four people is using social media. Whether they are sharing a funny cat video, advice on dating, or their personal experiences living with a chronic illness, there are nearly two billion people connecting with one another through Facebook, Twitter, Instagram, LinkedIn, and other social platforms, forever transforming the way humans communicate. This social media ecosystem also is ushering in a “digital health revolution.” Whether through their desktops, laptops, or mobile devices, people seeking medical and wellness information first check with their social networks.

Pharmaceutical companies have started entering the social media waters – — most with one toe in first. Given the increasing dependence on the digital world, social media is a natural touch point for companies to connect with the patients and healthcare providers (HCPs) they serve. Becoming truly social has not been an easy proposition for a conservative industry. But we have reached a tipping point, where social interaction is becoming critically important for the industry, and one that is blowing the lid off of the traditional way of communicating with stakeholders.

In the old paradigm, a pharmaceutical brand issues an advertisement that directs patients and HCPs to a website where they are provided one-sided information and an overall static experience. Patients are then directed to “talk to your doctor,” and that is where the interaction ends. Within the new social paradigm, patients, HCPs and pharmaceutical companies can have real conversations about the topics that are important to all of them. Patients also can access information and answers to their questions much faster, thereby making their path to help shorter.

Pharmaceutical companies have an opportunity to interact with patients and HCPs in a more meaningful way through social media. At Ogilvy, we are helping our pharmaceutical clients navigate this new paradigm and create unbranded social networks that offer patients who have similar life experiences – — whether that is quitting smoking or managing cancer – — a safe and comfortable environment to listen, learn, and share. We believe these networks offer unique value to the industry, allowing companies to provide patients with a support system where such a community may not otherwise exist.

Social networks resolve the limitations of both time and geography that are inherent with in-person support groups. They allow people to access information targeted to their concerns and conversations with global peers at any hour from the comfort and privacy of their own couch. Social networks also empower patients to initiate and direct conversations, interacting in a way that is meaningful to them. These networks are already forming, and we believe it is vital for industry to take the lead, to serve as the connector of those conversations, and to interact so that patients are assured they are receiving the best quality and most credible information.

The social media world has clearly shifted communication patterns and habits. Pharmaceutical companies can no longer afford to remain disconnected. Social interaction and sharing will continue whether or not the industry gets more involved. By taking a more active role within these patient communities, a pharmaceutical company allows its own voice and expertise to be heard, provides its stakeholders with real value, and, equally important, ensures that competitors aren’t the only ones creating meaningful interactions and relationships with consumers.

http://www.emarketer.com/Article/Social-Networking-Reaches-Nearly-One-Four-Around-World/1009976
http://www.businessinsider.com/social-media-engagement-statistics-2013-12

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Branding, Digital, Direct-to-Consumer, Healthcare Communications, Marketing, Media, Pharmaceutical, Public Relations, Social Media, Strategy, Technology | Comments closed
Mar11

Are You Harnessing the Power of Video in Healthcare Yet?

Young woman with gold fish tankDid you realise that the average attention span of a person has dropped to only 8 seconds? That’s one second less than a goldfish!

Video can combat this. It is a fantastic way to hook people in and capture their attention. Online video is growing so quickly that this is an opportunity that’s impossible to ignore:

  • Views on mobile devices have increased 400% in the past 2 years
  • YouTube is now the second most popular search engine behind Google, with 40% of its traffic coming from mobile
  • 80% of online visitors will watch a video all the way through, compared with 20% who will read a webpage

Patients are being diagnosed via video, surgeons are swapping clips on operation techniques, and, as everyone is rapidly becoming more and more mobile-connected, healthcare knowledge sharing will soon have no boundaries.

It’s likely that for whatever purpose, be it for a symposium or for patient education, your video will end up online, where it will receive the majority of its views. But it’s a noisy world out there, and one rule is key: keep it short, smart, and snappy.

What kind of video content should you choose?

The great news is that there are all kinds of exciting options that won’t break the budget. Think about who the audience is and how they’ll be watching. Are they using a small screen? With or without sound? On social media? Or at a live presentation…could Dr Smith at the back please put his mobile down and watch? (Hopefully if he enjoys it he’ll search for it later online, “like” it and share with his colleagues.)

Explore the different ways to cThe Other Sideonnect with your audience. Enriched video content is great for increasing user engagement, and interactive user-defined storytelling can be a totally immersive experience. It lets you get the right messages to each individual user by letting them click on objects in the video to influence what they see. “Choose a Different Ending” is a beautiful example of a great campaign tackling knife crime that drew immediate response. And another of the best ones I’ve seen recently is The Other Side of Honda.”

Or, if you need to get more complex data across in a way that quickly informs and engages, use an animated infographic to make data come alive. These motion graphics pack a huge visual punch, are bursting with information, and are rapidly becoming key tools to promote branded messages. For a truly multi-layered, fast and constantly moving example with beautiful visual transitions, you can’t beat “STUXNET: The Virus That Almost Started WW3.”

Whatever you want to achieve, remember you’re not alone. We recommend that you use a Creative and Motion team to help you get all those questions answered on the way to making great videos.

Video is a super strategy to stand out from the competition and it’s definitely a healthcare trend that’s already here and set to keep on growing.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Analytics, Apps, Blogging, Branding, Data, Design, Digital, Media, Public Relations, SEO, Social Media, Statistics, Strategy, Technology | Tagged | Comments closed
Jan7

Computational Lexical Analyses and the Modern Era of Wordsmithing

Writing Blog ImageIn a world fast becoming more interested in, impressed by, and capable of producing brilliant digital imagery, I’m the unfortunate one who gets to sit here and try to remind everyone that words still matter. Excited yet? Give me four minutes of your time, this is a brief post.

We work in what is first and foremost an advertising agency. There may be individual groups whose work is not entirely captured by that description (mine is one of them), but it’s the most condensed way of summarizing Ogilvy CommonHealth. Visually and creatively, the work that comes from many of our groups is stunning. It’s often best-in-class, and I’m not here to deter anyone from thinking so.

But this brings me back to what this post is about. Words, or language. Awe-inspiring as the visual work may be, our clients still often struggle with questions like, “What do we actually call this drug? How do we define and describe its therapeutic effect? How do we communicate that to clinicians? To patients?” Basic as these questions may seem, they are fundamental to the immediate and sustained success of the product. A drug needs a consistent, precise, ownable and differentiating lexicon in addition to a strong marketing campaign.

Easier said than done. Language is organic, a living, breathing document that evolves over time. Let’s look at the word good as an example. Once universally and unambiguously having meant desirable or of high quality, a recent article titled “The Art of the Amateur Online Review” in the New York Times describes why that’s no longer the case (the article is a good, quick read for anyone in advertising). Analyses of users’ product reviews show that good is starting to mean ambivalent. Reviewers say things like “it’s good, but….” In other words, good no longer means desirable, but simply good enough.

The same issues present themselves in a medical and scientific context. Clients wonder if they should say their drug is targeted or selective or honing. Perhaps others have created a drug with a new mechanism of action and they want to describe it in not just a differentiating way but also in a meaningful and exciting one. In medical language, the same words can have unique meanings across different categories.

Tools are available to help guide these decisions. In a computational lexical analysis, we can generate a database of language relevant to whatever subject area it is that we’re interested in. That can help us to know how the words in the category are used, and to see what opportunities there may be to create new language. It’s grounded in data, but this is a strategic exercise that seeks to provide guidance around what language is most appropriate for a given molecule/condition/category. Have a client with problems like this? Send them our way, we may be able to help.

 

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Branding, copy writing, copywriting, Creativity, Culture, Design, Healthcare Communications, Strategy | Tagged | Comments closed
Oct29

Exploring the Programmatic Opportunity in Healthcare Professional Media

JS Blog2You don’t have to be an expert in the intricacies of programmatic media buying to understand the rapid adoption of this latest innovation in the online advertising space. According to a recent AOL survey, 76% of advertisers buy display banners via programmatic across all industries and an estimated 9.5% of the total online media investment is being bought programmatically (WFA Survey, Aug 2014). Quite simply, large-scale advertisers have realized many benefits. Recognizing the potential, Ogilvy CommonHealth Medical Media first started offering the option to our medical advertising clients back in 2012 via our in-house Demand Side Platform (DSP) technology. Four years later, we review the fundamentals of the technology and the potential benefits to professional medical advertisers, while discussing the unique market conditions our industry faces that have hindered adoption. Ultimately, we ask, “Is programmatic buying right for advertisers looking to reach busy medical professionals?”

What Is Programmatic Buying?

Making banner buys programmatic simply means automating the process via a “machine” called a Demand Side Platform (DSP). Banner buys can be programmatic with or without the element of bidding (real-time bidding, or RTB), in which case two or more advertisers compete simultaneously for the same impression, with the win going to the highest bidder. The “machine” or technology not only automates the buying process, it analyzes first- and third-party data feeds to define custom audiences and then finds these targets as they move throughout the web via banner impressions available through ad exchanges. The DSP is a comprehensive solution that assists buyers by managing data, inventory and bids.

What Is the Opportunity?

The immediate opportunity for industry is to exponentially increase brand exposure and reduce costs by targeting healthcare professionals as they move across the web, beyond pure play medical sites such as Medscape and MedPageToday. The professional medical media sector continues to rely primarily on the direct 1:1, agency: publisher buying model. Given that most medical sites have a limited supply of inventory, banner CPMs are high, often averaging over $100.00 ($250.00-$350.00 for targeted banners) and premium publishers sell out of annual inventory very quickly. The DSP model solves the inventory supply problem and simultaneously yields cost-efficiency gains. With the ability to serve banners across the web to a qualified audience, we have realized CPMs downward of $20.00.

What Are the Challenges?

In the highly regulated pharma sector, we can expect to encounter challenges with the prospect of reaching a physician on ESPN.com or other nonclinical environment. Privacy concerns have been paramount but not insurmountable. Many leading pharma and medical publishers have revisited registration and opt-in language on their websites in order to broaden the use of captured data. Even when site categories are tightly constricted to news, weather and travel sites, control over ad placement and content adjacency may be compromised, which can lead to concerns for brand safety. Additionally, regulatory teams remain apprehensive around serving HCP-targeted creative on consumer-centric, nonmedical sites.

If the DSP only tapped into medical inventory, these challenges could be better addressed. However, the fundamentals of programmatic buying would be turned upside down, negating many of the benefits:

  • Scale: Inventory on medical sites is limited and finite.
  • Quality: As the stewards of physician member/user data, premium healthcare publishers such as medical societies will not relinquish inventory to an exchange.
  • Efficiency: CPMs could easily surge to over $400.00 to reach the most productive physicians.
  • Demand: There is a definite cap on what professional media buyers are willing to pay for banners as a tactic—regardless of who could potentially see the ad.

Our Viewpoint

In order to realize the efficiencies of programmatic buying against a professional medical audience, advertisers must work with a partner that can tap into large-scale general market ad exchanges while validating targets on the physician level. This would provide the inventory scale needed to drive CPMs down but ensure a professional message is delivered to an appropriate audience.

Despite ongoing buzz around the launch of an industry-specific programmatic buying platform whereby HCP publishers would exclusively place inventory they are willing to sell via automation with a single media buying agency, the concept has not yet been realized. Full-service media agencies have programmatic capabilities, and given that quality, transparency and neutrality would be compromised in such a scenario, there seems little incentive for media buyers at large to work through a third-party media buying agency. The key questions:  How would advertisers be assured they had a fair bid for the most premium inventory, and how would optimizations across multiple campaigns be neutrally managed, given the size of the audience?

As discussed, retargeting professionals strictly on medical sites has some challenges. Even so, medical publishers willing to try programmatic selling on their sites should continue to work directly with all media agencies, but offer programmatic direct deals. This type of transaction closely mirrors a direct 1:1 digital sale since the inventory and pricing are negotiated and guaranteed. However, elements of the buy are automated from the RFP through campaign management. Neutrality, quality, control and transparency would remain intact, as media buyers would not be required to buy via a third-party agency and the publishers could maintain control over ad messaging, placement and user data on their sites.

There is certainly room in the medical media sector to innovate. But given the unique characteristics of our market, going programmatic may not translate into greater banner revenue for medical publishers if demand is weak and advertisers are not willing to participate due to inflated CPMs. Specialized medical publishers would be better served to innovate offerings beyond banner advertising—lead generation, native advertising, and real-time dynamic content opportunities are just a few that are long overdue.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Design, Digital, Healthcare Communications, Marketing, Media, Media Placement | Tagged | Comments closed
Jul9

Is Print Dead?

4144823A lot has changed in print production since I entered advertising in 1987. Back in the day, printing was a form of art. A good printer was worth his or her weight in gold.

But how times have changed! Especially within the last four to five years. Art has taken a back seat, and it is down to price and speed. So what is a print buyer to do in this day and age? Is print going the way of the dinosaurs?

As I think about it, reviewing the latest research and trend reports, I have mixed feelings. I am a print person, I need it in my hand, but that doesn’t stop me from appreciating the digital world. It simply amazes me how far we have come since I started in this business. Google, YouTube, Pinterest, etc. You can find anything you need within seconds. How cool is that?

But hear this! Print is not dead and still has an important place. Just as radio did not bring the death of newspaper, and television did not bring the death of radio, online media will not kill off print media. A wise marketing plan must include a combination of both digital and print. Target your audience, apply segmentation, and adapt the resource allocation based on how your stakeholders prefer to receive their information. And of course, overlayed with analytics!

Print continues to have undeniable advantages over online advertising. It is narrowly targetable, highly personal, and credible to consumers. People trust the printed page. Audience specificity is guaranteed when trying to reach your customers.

In addition, print is tactile, a comfort food for the brain. Consumers are more engaged reading print, unlike websites, which are often skimmed in as little as 15 seconds. Studies have shown that people read digital screen text slower than printed paper and read less of it.

Technology is playing a vital role as well in print. Through the Ogilvy Innovation Lab and emerging technology, unique advances in printing—such as embedding video, QR codes and even adding smell into print—have not only made this channel more interactive, but more engaging as well.

Print is also relatively long-lived while being a solid vehicle for establishing brand identity. Print advertising will continue to be a viable component for an effective multichannel campaign. Understand your customers and how they want to receive information on your product by using the right vehicles:  real-time analytics will help inform your mix of online, print, collateral and event marketing to ensure your campaign is a winner.

So don’t ignore print. It still plays an important role in your brand’s promotional campaign. I just can’t help wondering how the next decade will affect the advertising world….

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at
blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, content marketing, Customer Relationship Marketing, Digital, Direct-to-Consumer, Media, Personal Reflections, Social Media, Technology | Tagged , , , , , , , | Comments closed
Jul2

FDA Social Media Draft Guidance Released June 2014

fdaLeading up to its final guidance to be released in July 2014, the FDA has released draft guidance on how pharmaceutical companies and medical device manufacturers should interact with social media platforms with regard to fair balance and brand messaging. The first part of the recently released recommendations is focused on how companies post advertising and promotional messages to Internet and social media platforms with character space  limitations, such as Twitter and Google Sitelinks. The second part of the recommendations addresses how pharmaceutical and medical device companies may correct independent third-party misinformation about their brands online. While this guidance is recommended and not required, it will be beneficial for pharmaceutical companies to adopt the FDA recommendations going forward.

A brief review of the FDA recommendations is listed below, along with suggestions for practical implementation.

Internet and social media platforms with character space limitations

In its draft guidance Internet/Social Media Platforms with Character Space Limitations—Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices, the FDA outlines its recommendations for promotion of brand and product information using Twitter and other character-space-limited communications, such as Google Sitelinks. The recommendations are direct and seek to include fair balance in each individual communication.

The most salient points are as follows:

  • Reminder communications, which call attention to the name of a product but do not make claims, are exempt from this guidance
  • The full indication must be used when making claims in a communication
  • Benefit information should be accompanied by risk information within each individual communication
  • The content of risk information presented should, at a minimum, include the most serious risks associated with the product
  • A direct link to a more complete discussion of risk information about the product must be included in the communication

While a link to the ISI is adequate in such communications, the FDA further recommends that companies develop landing pages devoted exclusively to the communication of risk information about their products (e.g., www.product.com/risk). The format for the URL and landing page should clearly communicate that the destination will explain the risks associated with the product.

Many social media tools automatically use link shorteners to keep within the character space limitations of the communications. While the FDA does not directly oppose the use of shorteners, it recommends that the resulting URL denote to the user that the landing page contains risk information. (For example, prod.uct/risk clearly communicates that the destination is about risk.) Another solution to character space limitations is for the company to register shorter domain names that can then redirect to its product sites for use in social media.

One challenge that brands with black box warnings will face following this guidance, especially on Twitter, is in fully communicating risk information within a single tweet. For such brands it will be impossible to communicate all risks in the platform-restricted space; therefore, we recommend against using Twitter as a channel to communicate those products’ indications, benefits, and risks.

The FDA guidance also extends to paid search communications, such as Google Sitelinks. The Sitelinks feature displays up to 6 additional destination URLs for users to choose from when a paid search ad is displayed. In complying with the FDA’s draft guidance, most of the additional destination URLs provided by the brand would link to risk information in an attempt at fair balance, which might portray the product as riskier than it actually is. This might deter some companies from using Sitelinks to promote their products.

Correcting third-party misinformation

The second round of draft guidance from the FDA, Internet/Social Media Platforms: Correcting Independent Third-Party Misinformation About Prescription Drugs and Medical Devices, seeks to improve the quality of public health information by allowing companies to correct third-party misinformation that they find online about their products. Again, these are recommendations; it is not required that a company respond to such misinformation, regardless of whether it appears on a company’s own forum or on an independent third-party forum or website.

The FDA defines misinformation as positive or negative representations or implications about a company’s product by an independent third party. There are two types of misinformation: a misrepresentation of the label, which a brand will typically want to correct, and an exaggeration of outcomes, which a brand may be tempted to leave uncorrected. The FDA recommends that companies respond to both types of misinformation.

If a company decides to correct misinformation on a third-party site, it should:

  • Provide corrective information and a link to corrective information
  • Post corrective information alongside the misinformation or refer to the misinformation in its response
  • Limit the scope of the corrective information to be specific to the misinformation, and keep it non-promotional
  • Correct positive misinformation as well as negative misinformation
  • Keep records of corrective interactions

The FDA clearly states that it will not hold a company accountable for an independent third party’s subsequent actions or lack thereof after corrective information has been supplied. Further, companies do not have to continue to monitor the third-party site after information has been corrected.

Going forward

While it is not feasible for a company to monitor all third-party sites for misinformation about its products, creating Google alerts (or similar) will help ensure that it is notified when user-generated content (UGC) about its products is trending. A company can then respond appropriately if they desire. However, consideration must be given to the level of time and effort that legal and regulatory teams must spend reviewing and filing the corrections versus the impact smaller third-party sites and individual bloggers can have on public health information.

Alternately, a company can and should focus its attention to more prominent third-party sites, such as WebMD, Wikipedia, and brand-specific hubs, in their quest to correct misinformation. This will maximize the intention of correcting the message while appropriately weighting the effort.

Overall, the draft guidance marks a significant milestone in the pharmaceutical industry’s ability to keep pace with other industries in the social media space where consumers are increasingly seeking out health information. This guidance has been a long time coming, and now pharmaceutical companies can jump into social media knowing they will be FDA compliant when the final guidance is released.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at
blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, content marketing, Health & Wellness, Healthcare Communications, Marketing, Social Media, Technology | Tagged , , , , | Comments closed
Jun26

Brain Candy: Byte-sized Creative Inspiration for Digital Minds—1st Edition

GKblogWhat I love about being an advertising creative is the eternal search for creative stimulus. Always on the search for something that turns your mind on, makes you “think different” and gets you excited to show your co-workers like it was a grade school show-and-tell.

But it’s this stimulus, or this search for stimulus, that really does inspire truly innovative ways to reach our fellow persons with a memorable experience. Sometimes it’s a cool social media tie-in, or maybe a super-sneaky hidden camera capture. Either way, it makes an impression on us and becomes a reference point for the next creative idea, the next killer pitch tactic.

I imagine everyone has his or her favorite sites to mine Internet gold. If you have a site like that, stop hoarding the good stuff and write the next Brain Candy post. Or maybe you just like calling people out for being “two-thousand and late” like an art director I know here at Ogilvy (who will go unnamed for now).

So for now, I’ve collected a few of my favorite inspirations over the last few months to share with you. I hope you find them as inspiring, hilarious and introspective as I did.

Before we dive in, have you seen the site This Advertising Life? No? Really? Then you have to go now… This should be daily viewing for all agency types.

OK, so here are some vids from across the interwebs that I think are pretty cool. Some of them actually lend themselves well as crossovers into the pharma world. But if you can’t sell-in selfies and Snapchat for the latest patient consumer pitch, at least you have some neat stuff to show before your weekly status meeting.

Every now and again you see something and think, “That is genius.” And you just sit at your computer in total awe of your self-contempt for not thinking of it first. Then you think about what must have been going on in that room for someone to have come up with it. Pure Genius.

 

How do you get a paper poster to turn into a musical instrument? I watched this video three times and I’m still amazed.

 

I guess you really can’t beat selfies, beer and Twitter. You have to love the Danes, and they definitely love their Carlsberg. Happy hour will never be the same.

 

This one has been making the rounds lately at the Chocolate Factory—a really impressive way to use augmented reality. We actually worked this into a pitch recently, and this is totally something you can build into a convention experience…minus the alien invasion, I would imagine.

 

I don’t mean to encourage duplicitous behavior, but you have to admit this is pretty funny. On the other hand, this is proof of concept for a CRM or patient reminder app. This app can pulse out reminder messages to patients to take their meds (adherence), get well soon (post surgical), have a good day (depression), or even send out appointment reminders.

 

I always loved reading about twin studies from clinical psych class. There’s something really cool about having such a perfect control for a study design. But multiples kind of freak me out in person though. Anyway, you should listen to your mother and not chew gum in mixed company, here’s why.

 

So you want to have a goof on that dude who’s using waaaaaaay too many hashtags? Here you go, courtesy of Axe. I encourage you all to try this, on yourself!

 

Now let’s close on a high note…if you’re somehow one of the 2 million people who have not seen this ad, just do it.

CONTINUE THE CONVERSATION:
Questions? Comments? You can contact the author directly at
blog@ochww.com.
Please allow 24 hours for response.

Also posted in advertising, Branding, Creativity, Culture, Digital, Humor, Media, Video | Tagged , , , , , | Comments closed